News headlines about Medifast (NYSE:MED) have been trending somewhat positive recently, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Medifast earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave news stories about the specialty retailer an impact score of 45.8415378990124 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Several analysts have commented on the stock. ValuEngine downgraded shares of Medifast from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Zacks Investment Research upgraded shares of Medifast from a “hold” rating to a “buy” rating and set a $81.00 target price on the stock in a report on Saturday, January 13th. Finally, DA Davidson lifted their price objective on shares of Medifast to $89.00 and gave the company a “buy” rating in a report on Friday, December 8th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $75.00.
Medifast (NYSE:MED) traded down $1.10 during midday trading on Friday, hitting $66.90. 94,695 shares of the stock were exchanged, compared to its average volume of 76,744. Medifast has a 12 month low of $40.00 and a 12 month high of $74.78. The firm has a market capitalization of $811.49, a P/E ratio of 32.96, a PEG ratio of 1.74 and a beta of 0.54.
Medifast (NYSE:MED) last posted its quarterly earnings data on Tuesday, November 7th. The specialty retailer reported $0.55 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.51 by $0.04. Medifast had a net margin of 8.58% and a return on equity of 24.07%. The company had revenue of $77.20 million for the quarter, compared to the consensus estimate of $74.94 million. During the same period last year, the company earned $0.51 earnings per share. The firm’s revenue was up 12.5% compared to the same quarter last year. analysts anticipate that Medifast will post 2.17 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, February 8th. Stockholders of record on Friday, December 22nd will be issued a $0.48 dividend. The ex-dividend date is Thursday, December 21st. This is an increase from Medifast’s previous quarterly dividend of $0.32. This represents a $1.92 dividend on an annualized basis and a dividend yield of 2.87%. Medifast’s dividend payout ratio (DPR) is 94.58%.
In related news, Director Glenn W. Welling sold 250,000 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $65.00, for a total value of $16,250,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Glenn W. Welling sold 275,000 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $64.60, for a total transaction of $17,765,000.00. The disclosure for this sale can be found here. 6.47% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Medifast (NYSE:MED) Share Price” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/03/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-medifast-med-share-price.html.
Medifast Company Profile
Medifast, Inc produces, distributes and sells weight loss, weight management, and healthy living products, and other consumable health and nutritional products. The Company’s product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products, and vitamins.
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.